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http://www.translational-medicine.com/content/11/1/235RESEARCH Open AccessLow-dose azathioprine is effective in maintaining
remission among Chinese patients with Crohn’s
disease
Jianghong Wu1, Yan Gao2, Chuanhua Yang1*, Xueqing Yang3, Xuhang Li4 and Shudong Xiao1Abstract
Background: Azathiopurine (AZA) is efficacious for maintenance remission of Crohn’s disease (CD) at the standard
dose of 2.0-2.5 mg/kg for Caucasian. It has been reported that the lower dose (1.0-2.0 mg/kg) in some Asian
countries was as effective as the standard dose. In the present study we analyzed the efficacy of <1.0 mg/kg AZA in
maintaining remission for Chinese patients.
Methods: The clinical data of all CD patients were reviewed from 1993 to December 2012. The patients who
initiated AZA treatment and were followed for ≥ 2 years with complete medical data were included. We divided
the patients into two groups according to their initial dose: <1.0 mg/kg group and 1.0-2.0 mg/kg group.
Results: Among 77 patients, 39 (50.6%) started treatment with <1.0 mg/kg AZA and 38 (49.4%) with 1.0-2.0 mg/kg.
The mean dose of <1.0 mg/kg group remained under 1.0 mg/kg at 6, 12 and 24 months, even if the doses were
adjusted according to efficacy and tolerance. The remission rate in patients of <1.0 mg/kg group was significantly
higher than that in those of 1.0-2.0 mg/kg group (P = 0.025). A dose of <1.0 mg/kg AZA was more commonly
associated with male gender, older age, heavier body weight and L1 location. Adverse events were observed in 21
of 77 patients (27.3%) and no significant difference in occurrence of adverse events or leucopenia between two
groups.
Conclusions: <1.0 mg/kg AZA was effective as 1.0-2.0 mg/kg in maintaining remission among Chinese patients
with CD.
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Crohn’s disease (CD) is an idiopathic chronic gastro-
intestinal inflammation of unknown etiology. Currently,
the goal of treatment is to control disease activity by in-
ducing and maintaining remission. In order to minimize
occurrence of the associated complications or the need
for surgery, patients have to take long-term medicines
to control activity of disease and prevent relapse. For
the maintenance of remission, immunomodulators
(such as thiopurines and methotrexate) and anti-tumor
necrosis factor-alpha monoclonal antibody have proven* Correspondence: dryangch3@163.com
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reproduction in any medium, provided the orto be highly efficient [1,2]. They not only decrease CD
clinical activity but also heal the mucosa of ulcers and
erosions [3,4], reduce the need for corticosteroids, and
improve the patient’s quality of life. In Asian countries,
particularly in developing countries such as China, anti-
tumor necrosis factor-alpha monoclonal antibody therapy
is very expensive, and most families can’t afford it, because
their health insurance doesn’t cover this therapy [5]. Thus,
cheaper and highly effective immunomodulators, particu-
larly azathiopurine (AZA), are widely accepted as the first-
line treatment by both patients and gastroenterologists.
Although severe side effects may occur [6,7], AZA has
been widely used globally for CD therapy.
In European patients, 2.0-2.5 mg/kg of AZA has been
shown to be effective against CD [8], and 1.0 mg/kg of
AZA has been confirmed to have no benefit [9]. However,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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recommended because Japanese patients are more suscep-
tible to dose-dependent adverse events [10]. Although a
higher dose of AZA has been observed to produce better
effects than a lower dose [11], it is not clear whether in
Asian patients low-dose (50–100 mg daily) AZA is as
effective as the standard dose for long-term maintenance
of remission. In China, where the incidence of CD is
rapidly rising, the number of patients dependent on im-
munomodulators has increased over the years [12]. In the
present study, we reviewed of all CD patients who under-
went AZA therapy at our medical center and analyzed the
efficacy and tolerance of AZA.
Methods
Patients population
The clinical data of CD patients from 1993 to December
2012 in Ren Ji Hospital, Shanghai Jiao Tong University
School of Medicine, Shanghai Institute of Digestive
Disease were reviewed. The diagnosis of CD was made
based on clinical, endoscopic, histopathological, radio-
logical findings and at least 6 months follow-up [13].
The patients who received AZA treatment and were
followed for ≥ 2 years were screened. Patients were ex-
cluded if 1) their medical data or follow-up data were
not complete; 2) they received anti-tumor necrosis
factor-alpha monoclonal antibody therapy for inducing
remission within three months before/after AZA therapy.
The disease activity was assessed by the Harvey and
Bradshow Index (HBI). Data regarding dosage, concomi-
tant medications, body weight, HBI, duration of remission,
efficacy and adverse events were collected from the med-
ical record or follow-up.
The decision for using AZA
The decisions of administrating AZA were: 1) frequent re-
lapse; 2) gastrointestinal stricture/obstruction; 3) fistulizing
CD; 4) prevention of postoperative recurrence; 5) steroid-
sparing agent for steroid-dependent or steroid-refractory;
6) moderate to severe CD. Clinical relapse was defined as
HBI >4 or need for re-introduce of steroids or occurrence
of new complications. Frequent relapse was defined as ≥2
relapses within 1 year. Steroid-dependence was defined as
relapse after the dosage of steroids tapered to 10 mg or re-
lapse within three months after steroids sparing. Steroid-
refractory was defined as no response towards full dose of
steroids for four weeks.
Treatment strategies
The patients, who were prescribed with AZA, were
monitored for full blood count once a week and liver
function tests every 2 weeks within 4 weeks at the start
of therapy, and monthly thereafter. The efficacy was
evaluated every three months.The definition of efficacy and toxicity
Remission was defined as HBI ≤4 or a decrease of at least
2 of HBI. Leucopenia was defined as white blood cell count
less than 3 × 109/l (normal range: 4 × 109/l-10 × 109/l);
Thrombocytopenia was defined as platelet count less
than lower border of normal range (<100 × 109/l). Hepatic
injury was defined as a liver function test above the
normal range.
Statistics
Doses were presented as mean ± SD. Remission rates
were expressed as a proportion with 95% confidence
interval (CI). The decisions for AZA treatment and
withdrawn were compared by chi-square. Clinical charac-
teristics between groups were analyzed by Student’s t-test,
chi-square, or Mann–Whitney U-test. Probabilities of
constant remission or off-steroid remission were calcu-
lated using the Kaplan-Meier statistical method and
tested using Log-rank test. A 2-sided P-value <0.05 was
considered statistically significance.
Results
In all, the data of 99 CD patients who started AZA
treatment before December 2010 were investigated.
Twenty-two patients were excluded: 8 (8.1%) due to
the lack of complete medical records or follow-up data
and 14 (14.1%) due to concomitant anti-tumor necrosis
factor-alpha monoclonal antibody therapy within 3
months of AZA therapy. Finally, 77 patients who met
the inclusion criteria were included in our study: 54
were male and 23 female. The mean age at the start of
AZA treatment was 32.2 years (range, 15–68 years).
The mean duration from diagnosis to AZA treatment
was 27.6 months (range, 0–240 months). Twenty-eight
patients (36.4%) had undergone abdominal operations
prior to AZA treatment. Age at diagnosis, disease
behavior and location were categorized according to
the Montreal classification [14]: 30 (39.0%), 10 (13.0%),
35 (45.5%), and 15 (19.5%) patients were classified as
L1 (ileum), L2 (colon), L3 (ilecolon), and L4 (upper
gastrointestinal tract) respectively; and 33 (42.9%), 40
(51.9%), 7 (9.1%), and 24 (31.2%) patients were classified
as B1 (nonstricturing, nonpenetrating), B2 (stricturing), B3
(penetrating), and p (perianal disease) respectively. The
decisions for using AZA were summarized (Table 1).
Dose of AZA
Seventy-four patients (96.1%) started treatment with
50 mg/d of AZA, two (2.6%) with 75 mg/d, and one
(1.3%) with 25 mg/d. The doses of AZA were adjusted
according to efficacy and tolerance (Table 2). Significantly
higher doses were administered in patients who didn’t
achieve remission compared to those who achieved re-
mission at 12 months (1.4 ± 0.4 versus 0.9 ± 0.2 mg/kg;
Table 1 Decisions for using azathioprine
Decisions All Patients with AZA <1.0 mg/kg group 1.0-2.0 mg/kg group P-value
(n = 77) (n = 39) (n = 38)
Gastrointestinal stricture/obstruction 37 19 18 0.854
Fistulizing CD 22 10 12
Frequent relapse 15 8 7
Moderate to severe CD 10 4 6
Prevention of postoperative recurrence 6 2 4
Steroid-sparing agent for steroid-dependent or steroid-refractory 6 4 2
18 cases contained more than one decision.
AZA azathioprine, CD Crohn’s Disease.
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kg; P = 0.005), but not at 6 months (1.0 ± 0.2 versus 1.0 ±
0.3 mg/kg; P = 0.828). In our cohort, almost half the
patients were treated with <1.0 mg/kg AZA. According
to their initial dose, we divided the patients into two
groups: <1.0 mg/kg group and 1.0-2.0 mg/kg group.
Within 2 years, the doses of six patients in each group
were adjusted: in <1.0 mg/kg group, four were in-
creased and two decreased, and in 1.0-2.0 mg/kg group,
five were increased and one decreased. The mean dose
of <1.0 mg/kg group remained under 1.0 mg/kg during
the 2 years, and a significant difference was found between
the two groups (Figure 1).
Efficacy of AZA treatment
The effect of AZA treatment was first evaluated at 6
months because remission was induced by corticosteroids
in 62 patients (80.5%), and the doses of corticosteroids
were continuously tapered during 3–6 months at the
start of AZA treatment. The overall remission rates of
all 77 patients at 0, 6, 12, and 24 months were 7.8%
(95% CI, 3.2%-16.8%), 70.1% (95% CI, 58.5%-79.8%),
53.2% (95% CI, 41.6%-64.6%), and 35.1% (95% CI,
24.8%-46.9%) respectively. The percentage of patients
who continued taking AZA at 6, 12, and 24 months
were 75.3% (95% CI, 64.0%-84.1%), 61.0% (95% CI,
49.2%-71.7%), and 50.6% (95% CI, 39.1%-62.1%) respect-
ively, and their remission rates were 93.1% (95% CI,
82.5%-97.8%), 87.2% (95% CI, 73.6%-94.7%), and 69.2%
(95% CI, 52.3%-82.5%) respectively. When remission
was achieved in relapsed patients after adjusting the
treatment regimens, the remission rates were 93.1%
(95% CI, 82.5%-97.8%), 93.6% (95% CI, 81.4%-98.3%),Table 2 Doses (mg/kg) of azathioprine at different time point
Mean dose Range dose Patients with <1.0 mg
Initial 1.0 ± 0.2 0.6-1.6 39 (50.6%)
6 Month 1.0 ± 0.3 0.4-1.7 29 (50.0%)
12 Month 1.0 ± 0.3 0.4-1.9 24 (51.1%)
24 Month 1.1 ± 0.3 0.4-2.1 17 (43.6%)and 92.3% (95% CI, 78.0%-98.0%) respectively; the over-
all remission rates of 77 patients at 6, 12, and 24 months
were 70.1% (95% CI, 58.5%-79.8%), 57.1% (95% CI,
45.4%-68.2%), and 46.8% (95% CI, 35.4%-58.4%) respect-
ively. A significant difference was observed in the remis-
sion rates of the <1.0 mg/kg group and 1.0-2.0 mg/kg
group (P = 0.0259) (Figure 2), and a significant differ-
ence was also observed in the off-steroid remission rates
between two groups (P = 0.0120). The decisions for
using AZA and the reasons for withdrawal of treatment
were listed and no significant difference was found
between the two groups (Tables 1 and 3).
Putative factors associated with low-dose AZA
(<1.0 mg/kg)
In our cohort, there were more male patients in <1.0 mg/kg
group than in 1.0-2.0 mg/kg group (P = 0.005). The mean
body weight was significantly greater in <1.0 mg/kg group
than in 1.0-2.0 mg/kg group (P < 0.001). In addition patients
in <1.0 mg/kg group were older (35.5 years old) than those
in 1.0-2.0 mg/kg group (28.7 years old) (P = 0.011), although
there was no significant difference in age at diagnosis
according to the Montreal classification. Locations signifi-
cantly differed between the two groups (P < 0.001): L3 was
more prevalent in 1.0-2.0 mg/kg group, while L1 was more
prevalent in <1.0 mg/kg group (Table 4).
Adverse events
Adverse events were observed in 21 of 77 patients (27.3%),
due to which 14 (18.2%) discontinued AZA therapy
(Table 5). Leucopenia occurred in 8 patients (10.4%), of
whom three discontinued therapy. Infection occurred in 2
patients (2.6%) (One suffered from perianal fistula infecteds




21 (53.9%) 1 (2.6%)








Adverse events 14 10 4 0.101
No response 3 0 3
Relapse 1 1 0
Patients’ intention 20 10Δ 10Δ
Total 38 21 17
ΔFour patients were aware of their white blood cells count <4 × 109/l (and
>3 × 109/l), and discontinued AZA therapy by their own choices.
AZA azathioprine.
Figure 1 Dose of azathioprine in <1.0 mg/kg group and 1.0-2.0
mg/kg group at different time points. The patients treated with
AZA were divided into <1.0 mg/kg group and 1.0-2.0 mg/kg group
according to their initial dose. The doses of AZA were adjusted
according to efficacy and tolerance during the 2-year period. The
mean dose of <1.0 mg/kg group remained under 1.0 mg/kg. * P < 0.01
compared the dose of <1.0 mg/kg group with 1.0-2.0 mg/kg group.
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after recovery by the patient’s choice; another suffered
from urinary tract infection). However, no significant
difference was observed in the occurrence of adverse
events or leucopenia between <1.0 mg/kg group and 1.0-
2.0 mg/kg group (Table 4).
Discussion
In Europe and the United States, the dose of AZA for
effective induction and maintenance of remission, as
recommended by consensus, is 2.0-2.5 mg/kg [1,8]. A
previous study has shown that for the majority of
Koreans, low-dose AZA (1.35 mg/kg, 105 patients) for
remission induction of inflammatory bowel disease was as
effective as the standard dose (2.25 mg/kg, 17 patients),
and 0.94-1.68 mg/kg was effective for CD maintenance.Figure 2 Cumulative probabilities of constant remission during
24 months using Kaplan-Meier statistical method.However, almost all patients in the low-dose group devel-
oped leucopenia or neutropenia, indicating that the doses
were too strong for the patients [15]. In Japan, 0.6-1.2 mg/
kg AZA was prescribed for patients with ulcerative colitis,
but only 17 out of 22 (77.3%) patients completed that 6-
month trial [16]. These reports suggest that in eastern
Asia, the suitable dose of AZA is much lower than the
standard, and that the effect of a <1.0 mg/kg dose of AZA
for maintenance of remission is limited. In the present
study on Chinese patients, the mean doses at 6, 12, and 24
months were 1.0, 1.0, and 1.1 mg/kg respectively, and al-
most half the patients were treated with <1.0 mg/kg AZA.
The efficacy of ~1.0 mg/kg AZA in maintaining remission
of CD was confirmed. Next, we compared the effect
of <1.0 mg/kg AZA with that of 1.0-2.0 mg/kg AZA
at 24 months, based on our previous result that the
severity of disease remained unaltered in 90% patients
with CD during the 2-year period [17]. To our surprise,
the remission rate in patients of <1.0 mg/kg group was
significantly higher than that in those of 1.0-2.0mg/kg
group. To explain this unexpected result, we further
analyzed the factors associated with <1.0 mg/kg group.
At our medical center, the doses of AZA were adjusted
according to efficacy and tolerance, and the doses of pa-
tients who did not achieve remission were significantly
higher than those of patients who achieved remission at
12 and 24 months. We do not know whether the
need-based escalation of doses in <1.0 mg/kg group
reached ≥1.0 mg/kg. The doses of six patients in each
group were adjusted: in <1.0 mg/kg group, four were
increased and two decreased, and in 1.0-2.0 mg/kg
group, five were increased and one decreased. The mean
AZA dose of <1.0 mg/kg group remained under 1.0 mg/
kg during the 2-year period, and was lower than that of
1.0-2.0 mg/kg group. Since the remission rate increased
after treatment regimens were adjusted, we were unable to
determine whether the patients discontinued AZA treat-
ment or whether the decisions for using AZA influenced
dose adjustment. No significant differences were observed
between the two groups with regard to the causes for
withdrawal of AZA treatment and the decisions for using
AZA. Adverse events were the main reason for AZA
Table 4 Characteristics of patients between <1.0 mg/kg group and 1.0-2.0 mg/kg group
Type All Patients with AZA <1.0 mg/kg group 1.0-2.0 mg/kg group P-value
(n = 77) (n = 39) (n = 38)
Gender
Male 54 33 21 0.005
Female 23 6 17
Age at AZA treatment 32.2 35.5 28.7 0.011
Duration from diagnosis to AZA treatment 27.6 25.7 29.5 0.683
Age at diagnosis
A1 5 2 3 0.112
A2 59 27 32
A3 13 10 3
Location
L1 30 24 6 <0.001
L2 10 5 5
L3 35 9 26
L4 15 9* 6*
Behavior
B1 33 19 14 0.342
B2 40 19 21
B3 7 2# 5#
P 24 11 13
Surgery history
Yes 28 15 13 0.698
No 49 24 25
Initial HBI 5.0 4.8 5.1 0.624
Initial body weight (kg) 52.9 60.5 45.2 <0.001
Concomitant with 5-ASA/SASP
At initial
Yes 50 29 21 0.079
No 27 10 17
At month 24
Yes 17 9 8 0.455
No 22 9 13
Adverse events
Yes 21 13 8 0.226
No 56 26 30
Leucopenia
Yes 8 4 4 1.000
No 69 35 34
*Including L4 coexist with L1or L3.
#Including B3 coexist with B2.
P for difference between <1.0 mg/kg group and 1.0-2.0 mg/kg group.
AZA azathioprine, HBI Harvey and Bradshow Index, 5-ASA 5-aminosalicylic acid, SASP sulfasalazine.
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cant difference was observed with respect to the occur-
rence of adverse events or leucopenia between the twogroups. In vivo, when AZA was concomitantly adminis-
tered with 5-aminosalicylic acid sulfasalazine (5-ASA/
SASP), the level of 6-thioguanine nucleotide significantly







Leucopenia 8 3 3
Hepatic Injury 7 5 4
Thrombocytopenia 1 1 1
Pancreatitis 1 1 1
Infection 2φ 1 1




Fatigue 1 1 1
Total 22 14 12
φIncluding both leucopenia and infection occurred in one patient.
5-ASA 5-aminosalicylic acid, SASP sulfasalazine.
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We hypothesize that the concomitant administration
of 5-ASA/SASP may be related to the lower dose AZA.
In the present study, no significant difference was found
with regard to the concomitant use of 5-ASA/SASP be-
tween the two groups at 0 and 24 months. Adverse events
were not significantly affected by the concomitant admin-
istration of 5-ASA/SASP between the groups.
Our results indicated that a dose of <1.0 mg/kg AZA
was more commonly associated with male gender, older
age, heavier body weight, and L1 location. Male gender
has been identified as a factor for long-term remission
[19,20], and in the present study it was also related with
low-dose AZA (<1.0 mg/kg). On the other hand, higher
rates of relapse were seen in female patients; their doses of
AZA had to be escalated. Older age was another factor for
long-term remission and young patients were prone to be
disabling CD [17,19-21]. Patients in <1.0 mg/kg group
were significantly older than those in 1.0-2.0 mg/kg group
at the start of AZA therapy, and the age (35.5 years) was
almost the same as that reported by Fraser AG et al., who
observed a lower relapse rate in the patients above 36
years of age [19]. Heavier body weight was also related
with low-dose AZA (<1.0 mg/kg). In fact, the patients with
heavier body weight suggested CD did not markedly influ-
ence the health of patients. In the previous reports, loca-
tion had no significant effect on the treatment of AZA,
except for colon, which was implicated to be associated
with remission [19,20]. In our cohort, only 10 (13.0%) pa-
tients were classified as L2, L1 (39.0%) and L3 (45.5%)
were the majority. Significant differences were seen with
regard to the locations between two groups: L3 was more
prevalent in 1.0-2.0 mg/kg group, while L1 was more
prevalent in <1.0 mg/kg group. It is plausible that patients
with larger extent of disease required higher dose of AZA
to maintain remission. Overall, male gender, older age,heavier body weight, and L1 location were associated with
long-term remission using <1.0 mg/kg AZA.
Leucopenia (white blood cells count <3 × 109/l) has been
reported to occur in 20-30% patients taking 2.0-2.5 mg/kg
AZA [22]. In the present study, leucopenia occurred in
10.4% patients. In fact, a white blood cell count of <4 ×
109/l was seen in 24.7% patients. If the patients were
aware of their low white blood cell counts (<4 × 109/l
and >3 × 109/l), they would have discontinued AZA
therapy by their own choices (eight patients in the
present study). Since there was no difference in the re-
lapse rates between leucopenic and non-leucopenic pa-
tients, we did not escalate the dose up to development
of leucopenia [15]. Our principle of prescription was to
adjust the dose of AZA according to the white blood
cell count and HBI: if HBI was <4 and AZA was well
tolerated, the same dose of AZA was continued. We
believed that some patients in our cohort were capable
of tolerating higher doses of AZA, but chose not to be-
cause their HBI was <4 and they were satisfied with the
therapy. Our patients’ wishes were always respected. Thus,
the principles of prescription practiced by our medical
center also contributed to the lower dose AZA.
Our results showed that in approximately half the
patients with CD, low-dose AZA (<1.0 mg/kg) proved
efficient for the maintenance of remission and the
principles of prescription applied by our medical center
was suitable. In Europe and in the United States, the dose
of AZA for CD patients is escalated every 2 weeks until
the target dose of 2.0-2.5 mg/kg is reached [23]. Western
and Eastern countries differ not only in the manifestations
of CD but also with regards to its treatment [12,24]. The
limitations of this study are its small sample size, retro-
spective nature and single-center design. A previous re-
port found that 2.0 mg/kg AZA was well tolerated by 11
of 13 Chinese patients [25] and that Singapore Asians
could tolerate 1.95 mg/kg AZA [26]. These results sug-
gest that a prospective, multicenter, large clinical trial is
necessary to confirm the efficacy of <1.0 mg/kg AZA
for long-term maintenance of remission in Chinese
patients with CD.Conclusions
In summary, in Chinese patients with CD, low-dose AZA
(<1.0 mg/kg) may be effective for the maintenance of re-
mission, and dose adjustment should be individualized
according to efficacy and adverse events.
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